Assessing long-term effects of imatinib and infliximab on long-COVID symptoms
Long-term Follow-up of a Randomized Multicenter Trial on Impact of Imatinib and Infliximab on Long-COVID in Hospitalized COVID-19 Patients
This study is testing whether the medications imatinib and infliximab can help people who were hospitalized for COVID-19 feel better and reduce long-COVID symptoms over two years.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Clinical Urology and Epidemiology Working Group Government |
| Drugs / interventions | infliximab, imatinib |
| Locations | 1 site (Helsinki) |
| Trial ID | NCT05220280 on ClinicalTrials.gov |
What this trial studies
The SOLIDARITY Finland Plus Long-COVID trial evaluates the long-term impact of imatinib and infliximab on patients who were hospitalized due to COVID-19. It aims to determine whether these medications can reduce the risk of long-COVID symptoms and improve quality of life over a two-year follow-up period. Participants will complete questionnaires at six months, one year, and two years post-discharge to assess their symptoms and overall well-being. The study follows a randomized, open-label design, comparing standard care with the addition of these treatments.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been hospitalized with laboratory-confirmed SARS-CoV-2 infection.
Not a fit: Patients with severe comorbidities or contraindications to the study drugs may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide new treatment options to alleviate long-COVID symptoms and enhance the quality of life for affected patients.
How similar studies have performed: Other studies have shown promise in using similar approaches for treating long-COVID, but this specific combination of treatments is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients, 18 years and above * SARS-2-CoV-2 infection, laboratory-confirmed * Admission to the hospital ward or ICU * Written informed consent prior to initiation of the study or a close relative/legal representative provides written informed consent prior to initiation of the study according to the presumed will of the patient when the patient is unable to give consent herself/himself. * No anticipated transfer within 72 hours to a non-study hospital Exclusion Criteria: * Estimated life expectancy under three months due to severe comorbidity * ASAT/ALAT-ratio over five-fold upper limit * Acute myocardial infarction or unstable angina pectoris * Breast feeding or pregnancy * Any reason why, in the opinion of the investigators, the patient should not participate * Patient participates in a potentially confounding drug or device trial during the course of the study * Already receiving any of the study drugs * Severe renal failure (eGFR \< 30 mL/min)
Where this trial is running
Helsinki
- University of Helsinki — Helsinki, Finland (Recruiting)
Study contacts
- Study coordinator: Kari AO Tikkinen, MD PhD
- Email: kari.tikkinen@helsinki.fi
- Phone: +358406510530
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.